Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Streptococcal Infections Overview 9 Therapeutics Development 10 Pipeline Products for Streptococcal Infections - Overview 10 Pipeline Products for Streptococcal Infections - Comparative Analysis 11 Streptococcal Infections - Therapeutics under Development by Companies 12 Streptococcal Infections - Therapeutics under Investigation by Universities/Institutes 13 Streptococcal Infections - Pipeline Products Glance 14 Clinical Stage Products 14 Early Stage Products 15 Streptococcal Infections - Products under Development by Companies 16 Streptococcal Infections - Products under Investigation by Universities/Institutes 17 Streptococcal Infections - Companies Involved in Therapeutics Development 18 Absynth Biologics Limited 18 AstraZeneca Plc 19 Centauri Therapeutics Limited 20 ContraFect Corporation 21 Emergent BioSolutions Inc. 22 GlaxoSmithKline Plc 23 Helix BioMedix, Inc. 24 Merck & Co., Inc. 25 MGB Biopharma Limited 26 Sealife PHARMA GMBH 27 Sequoia Sciences, Inc. 28 Sumitomo Dainippon Pharma Co., Ltd. 29 Trellis Bioscience, Inc. 30 Wellstat Vaccines, LLC 31 Streptococcal Infections - Therapeutics Assessment 32 Assessment by Monotherapy Products 32 Assessment by Target 33 Assessment by Mechanism of Action 35 Assessment by Route of Administration 37 Assessment by Molecule Type 39 Drug Profiles 41 ATx-201 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 AZ-6142 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 CF-305 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 EV-035 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 firmocidin - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 HB-1345 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 J8-CRM197 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 MGBBP-3 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Monoclonal Antibodies for Group A Streptococcus Infections - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 Monoclonal Antibody to Inhibit Coagulase for Streptococcus Infections - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 Polysaccharides for Streptococcal Infections - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 SLP-0901 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 SLP-0905 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 SM-295291 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 SM-369926 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Small Molecules for Bacterial Infections - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Streptococcus (trivalent) vaccine - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 streptococcus [serotype B] (multivalent) vaccine - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 Streptococcus pyogenes (30-valent) vaccine - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 Streptococcus pyogenes vaccine - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 Streptococcus pyogenes vaccine - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 Streptococcus pyogenes vaccine - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 Streptococcus vaccine - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 Streptococcal Infections - Dormant Projects 72 Streptococcal Infections - Discontinued Products 74 Streptococcal Infections - Product Development Milestones 75 Featured News & Press Releases 75 Aug 25, 2015: Streptococcus Vaccine Developed by UTHSC Professor of Medicine James B. Dale to Begin Clinical Trial 75 Jun 01, 2015: Researchers create new combination vaccine to fight Streptococcus A 75 Appendix 77 Methodology 77 Coverage 77 Secondary Research 77 Primary Research 77 Expert Panel Validation 77 Contact Us 77 Disclaimer 78

List of Tables Number of Products under Development for Streptococcal Infections, H1 2016 10 Number of Products under Development for Streptococcal Infections - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Number of Products under Investigation by Universities/Institutes, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Development, H1 2016 15 Products under Development by Companies, H1 2016 16 Products under Investigation by Universities/Institutes, H1 2016 17 Streptococcal Infections - Pipeline by Absynth Biologics Limited, H1 2016 18 Streptococcal Infections - Pipeline by AstraZeneca Plc, H1 2016 19 Streptococcal Infections - Pipeline by Centauri Therapeutics Limited, H1 2016 20 Streptococcal Infections - Pipeline by ContraFect Corporation, H1 2016 21 Streptococcal Infections - Pipeline by Emergent BioSolutions Inc., H1 2016 22 Streptococcal Infections - Pipeline by GlaxoSmithKline Plc, H1 2016 23 Streptococcal Infections - Pipeline by Helix BioMedix, Inc., H1 2016 24 Streptococcal Infections - Pipeline by Merck & Co., Inc., H1 2016 25 Streptococcal Infections - Pipeline by MGB Biopharma Limited, H1 2016 26 Streptococcal Infections - Pipeline by Sealife PHARMA GMBH, H1 2016 27 Streptococcal Infections - Pipeline by Sequoia Sciences, Inc., H1 2016 28 Streptococcal Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 29 Streptococcal Infections - Pipeline by Trellis Bioscience, Inc., H1 2016 30 Streptococcal Infections - Pipeline by Wellstat Vaccines, LLC, H1 2016 31 Assessment by Monotherapy Products, H1 2016 32 Number of Products by Stage and Target, H1 2016 34 Number of Products by Stage and Mechanism of Action, H1 2016 36 Number of Products by Stage and Route of Administration, H1 2016 38 Number of Products by Stage and Molecule Type, H1 2016 40 Streptococcal Infections - Dormant Projects, H1 2016 72 Streptococcal Infections - Dormant Projects (Contd..1), H1 2016 73 Streptococcal Infections - Discontinued Products, H1 2016 74 List of Figures Number of Products under Development for Streptococcal Infections, H1 2016 10 Number of Products under Development for Streptococcal Infections - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Number of Products under Investigation by Universities/Institutes, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Products, H1 2016 15 Assessment by Monotherapy Products, H1 2016 32 Number of Products by Top 10 Targets, H1 2016 33 Number of Products by Stage and Top 10 Targets, H1 2016 33 Number of Products by Mechanism of Actions, H1 2016 35 Number of Products by Stage and Mechanism of Actions, H1 2016 35 Number of Products by Routes of Administration, H1 2016 37 Number of Products by Stage and Routes of Administration, H1 2016 37 Number of Products by Molecule Types, H1 2016 39 Number of Products by Stage and Molecule Types, H1 2016 39

Absynth Biologics Limited AstraZeneca Plc Centauri Therapeutics Limited ContraFect Corporation Emergent BioSolutions Inc. GlaxoSmithKline Plc Helix BioMedix, Inc. Merck & Co., Inc. MGB Biopharma Limited Sealife PHARMA GMBH Sequoia Sciences, Inc. Sumitomo Dainippon Pharma Co., Ltd. Trellis Bioscience, Inc. Wellstat Vaccines, LLC